JOSEPH P. LYSSIKATOS Synthetic and Medicinal Chemistry

EDUCATION · Ph.D. - Synthetic Organic Chemistry

EXPERIENCE · BioPharmaWorks - 2018 → ; Pfizer - 1992 →  2001, Array Biopharma - 2001 →  2007, Genentech - 2007 →  2014, Biogen - 2014 →  2015, Denali- 2015→  2017, Abbvie-Stemcentrx- 2017-2019.  Oncology, Neuroscience, Immunology, Antibacterials, Pain, Medicinal Sciences.

EXPERTISE · Synthetic Chemistry, Medicinal, and Structure-based drug design, DMPK, and Molecular Toxicology.  Over 250 issued patents and scientific publications and a co-inventor of MEKTOVI™ (Binimetinib) and co-discoverer of 16 clinical candidates (12 of which still in various phases of clinical trials).

BIO

Joe has worked in antibacterials, immunology, cancer and neuroscience over his career at seven pharmaceutical companies achieving top scientific roles and leadership Medicinal Chemistry and DMPK positions.   He led and was a key scientific contributor (co-inventor) of >30 programs which resulted in the discovery of 23 development candidates.  Fifteen of these were advanced into the clinic: 11 of which tested in various phases of clinical trials.  Most notably crenolanib, selumetinib, binimetinib, varlitinib tosylate, filanesib, motolimod and tucatinib (ARRY-380/ONT-380). He is a co-inventor of the Mektovi (binimetinib) component of the FDA approved melanoma drug combo Braftovi/Mektovi. I also played a small, but key role that helped enable the discovery of Chantix.  An inventor on 150 issued patents and a co-author of 57 papers, Joe brings his broad experience and exposure to drug discovery to BioPharmaWorks and their collaborators.